Daniel Fries is an entrepreneur and writer. He is the co-author of two highly-cited papers in the field of translational oncology research. Dan’s diverse background includes positions as a research associate at OSI Pharmaceuticals, an associate scientist at Medtronic Cardiovascular, and research scientist at both the Michigan Center for Translational Pathology and the Meyerson Lab at Dana Farber of Harvard Medical School. Currently, Dan manages and operates a portfolio of internet companies, and has partnered with Wired Investors to help grow the company the in the rapidly expanding micro-private equity space. Dan holds a BS/BA in molecular biology and Spanish from the University of Michigan. He speaks Spanish fluently and currently splits most of his time in between startup incubators in Chicago, Saigon, and Mexico City. He is fascinated by the potential of exponential technologies in both biotech and cryptocurrency.